BioIVT

BioIVT provides primary cells, tissue samples, blood products, and subcellular fractions from both human and animal sources. Key products include cryopreserved hepatocytes, tissue microarrays, and disease-state plasma. These materials are widely used in ADME toxicology, drug metabolism, and pharmacokinetic studies.

The firm operates its own Institutional Review Board (IRB)-approved donor programs and clinical collection networks. BioIVT manages informed consent, donor screening, and regulatory compliance directly, rather than relying on third-party aggregators. This controlled chain of custody is a core part of its value proposition to pharmaceutical clients.

BioIVT's specimens support preclinical drug discovery, biomarker validation, and in vitro diagnostic assay development. Researchers use its hepatocytes for metabolic stability profiling and its disease-state blood products for companion diagnostic calibration. The firm's materials are also used in cell-based potency assays required by regulatory submissions.

Yes, BioIVT maintains donor programs, processing labs, and logistics hubs across North America and Europe. Its international footprint allows the firm to source diverse donor populations and deliver fresh samples to clients in multiple regions. This network was expanded in part through acquisitions of European biospecimen providers.

BioIVT focuses on pre-clinical and research-grade specimens rather than commercial drug distribution. While logistics providers move investigational drugs between trial sites, BioIVT supplies the actual biological starting material — cells, tissues, and plasma — that researchers use to test candidate molecules before human trials. Its value is in the quality and characterization of the specimen itself, not the distribution network.